AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
It is long past time for Congress to strengthen our nation's safety laws regarding drugs and medical devices.
Over the past two years, numerous deaths and injuries have been linked to certain prescription medications and medical devices. Common to these cases is the fact that the manufacturers--and the Food and Drug Administration, which approved the products--downplayed a problem or kept it from the public for months or years.
Some drugs carry risks that should have been detected and publicized earlier (see "Prescription for Trouble," page 34). In some cases, the drugmaker withheld safety risks from the public.
Consumers face unnecessary risks because of weak laws and a seeming lack of will by FDA leadership to challenge the pharmaceutical industry. Critics both inside and outside the agency say the emphasis has shifted in recent years to approving drugs--in some cases new therapies,but mostly "me too" drugs that mimic ones already being sold--at the expense of safety monitoring once they are on the market.
Flaws in the drug-safety system were dramatically exposed in 2004, when the arthritis pain medication Vioxx was removed from the market. An estimated 139,000 heart attacks, strokes, and other serious complications had been linked to the drug, which was heavily marketed by Merck even though the company and the FDA had known of the safety risks since 2000, when the first study of the drug raised concerns.
Similarly, GlaxoSmithKline, maker of the antidepressant Paxil, had studies dating back to 1998 showing an increased risk of suicide in children and teenagers. GSK never published that information. It was not until October 2004 that the FDA at last required the strongest safety warning on Paxil and other antidepressants.
Little has been done to prevent such problems.The ...